Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). We sought to describe T790M changes in serum/plasma during osimertinib therapy and correlate...
| Authors: | ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Publication date: | 2018 |
| Country: | España |
| Institution: | Universitat Autònoma de Barcelona |
| Repository: | Dipòsit Digital de Documents de la UAB |
| Language: | English |
| OAI Identifier: | oai:ddd.uab.cat:238826 |
| Online Access: | https://ddd.uab.cat/record/238826 https://dx.doi.org/urn:doi:10.18632/oncotarget.25478 |
| Access Level: | Open access |
| Keyword: | EGFR-T790M mutation Serum/plasma Osimertinib Acquired resistance EGFR tyrosine kinase inhibitors |
| _version_ | 1878738505875587072 |
|---|---|
| author | Morán, Teresa |
| author2 | Felip, Eudald|||0000-0002-3812-1313 Bosch-Barrera, J.|||0000-0002-0893-7821 de Aguirre, Itziar Ramirez, Jose Luis Mesia, Carles Carcereny, Enric|||0000-0001-5235-5602 Roa, Diana Sais, Elia García García, Yolanda|||0000-0002-0280-4382 Blanco, Remei|||0000-0001-6748-0326 Sanchez, Silvia Villacorta, Claudia Rosa Queralt, C.|||0000-0001-9875-0173 Velarde, Jose María Rosell, Rafael|||0000-0003-0817-3400 |
| author2_role | author author author author author author author author author author author author author author author |
| author_browse | Blanco, Remei|||0000-0001-6748-0326 Bosch-Barrera, J.|||0000-0002-0893-7821 Carcereny, Enric|||0000-0001-5235-5602 Felip, Eudald|||0000-0002-3812-1313 García García, Yolanda|||0000-0002-0280-4382 Mesia, Carles Morán, Teresa Queralt, C.|||0000-0001-9875-0173 Ramirez, Jose Luis Roa, Diana Rosell, Rafael|||0000-0003-0817-3400 Sais, Elia Sanchez, Silvia Velarde, Jose María Villacorta, Claudia Rosa de Aguirre, Itziar |
| author_facet | Morán, Teresa Felip, Eudald|||0000-0002-3812-1313 Bosch-Barrera, J.|||0000-0002-0893-7821 de Aguirre, Itziar Ramirez, Jose Luis Mesia, Carles Carcereny, Enric|||0000-0001-5235-5602 Roa, Diana Sais, Elia García García, Yolanda|||0000-0002-0280-4382 Blanco, Remei|||0000-0001-6748-0326 Sanchez, Silvia Villacorta, Claudia Rosa Queralt, C.|||0000-0001-9875-0173 Velarde, Jose María Rosell, Rafael|||0000-0003-0817-3400 |
| author_role | author |
| collection | Dipòsit Digital de Documents de la UAB |
| description | Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). We sought to describe T790M changes in serum/plasma during osimertinib therapy and correlate these changes with treatment outcomes. Serum/plasma from EGFR -mutant lung cancer patients with T790M-AR was collected before and during osimertinib treatment. Changes in T790M were evaluated using a peptide-nucleic acid-PCR assay, and correlated with clinical and radiographic response. Thirteen patients were included. Median time on osimertinib treatment was 10.6 months with a median progression-free survival of 13.6 months. Best response to osimertinib was partial response (PR), stable disease (SD) or progression (PD) in 46.1%, 30.8% and 23.1% of patients, respectively. Most of the patients were paucisymptomatic at baseline. Symptom improvement was reported in 66.6% of responder patients; while symptoms remained stable in 75% of patients with SD, and 66% of patients with PD had clinical deterioration. Three patterns of T790M changes during osimertinib treatment were identified. T790 remained detectable with PD or a short-lasting SD in 15.4% of the patients. T790M disappeared in 69.2% of patients with PR or SD. T790M disappeared, despite clinical and/or radiographic progression in 15.4% of the patients. Changes of T790M in serum/plasma in EGFR -mutant lung cancer patients with T790M-AR might be a useful marker of symptomatic and radiographic outcome to osimertinib. Longer follow-up is needed to establish if subsequent emergence of T790M could be a marker of resistance. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_b01ac236e51aa329aed2ee817693a006 |
| institution | Universitat Autònoma de Barcelona |
| instname_str | Universitat Autònoma de Barcelona |
| language | eng |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:ddd.uab.cat:238826 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| reponame_str | Dipòsit Digital de Documents de la UAB |
| spelling | Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer Morán, Teresa Felip, Eudald|||0000-0002-3812-1313 Bosch-Barrera, J.|||0000-0002-0893-7821 de Aguirre, Itziar Ramirez, Jose Luis Mesia, Carles Carcereny, Enric|||0000-0001-5235-5602 Roa, Diana Sais, Elia García García, Yolanda|||0000-0002-0280-4382 Blanco, Remei|||0000-0001-6748-0326 Sanchez, Silvia Villacorta, Claudia Rosa Queralt, C.|||0000-0001-9875-0173 Velarde, Jose María Rosell, Rafael|||0000-0003-0817-3400 EGFR-T790M mutation Serum/plasma Osimertinib Acquired resistance EGFR tyrosine kinase inhibitors Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). We sought to describe T790M changes in serum/plasma during osimertinib therapy and correlate these changes with treatment outcomes. Serum/plasma from EGFR -mutant lung cancer patients with T790M-AR was collected before and during osimertinib treatment. Changes in T790M were evaluated using a peptide-nucleic acid-PCR assay, and correlated with clinical and radiographic response. Thirteen patients were included. Median time on osimertinib treatment was 10.6 months with a median progression-free survival of 13.6 months. Best response to osimertinib was partial response (PR), stable disease (SD) or progression (PD) in 46.1%, 30.8% and 23.1% of patients, respectively. Most of the patients were paucisymptomatic at baseline. Symptom improvement was reported in 66.6% of responder patients; while symptoms remained stable in 75% of patients with SD, and 66% of patients with PD had clinical deterioration. Three patterns of T790M changes during osimertinib treatment were identified. T790 remained detectable with PD or a short-lasting SD in 15.4% of the patients. T790M disappeared in 69.2% of patients with PR or SD. T790M disappeared, despite clinical and/or radiographic progression in 15.4% of the patients. Changes of T790M in serum/plasma in EGFR -mutant lung cancer patients with T790M-AR might be a useful marker of symptomatic and radiographic outcome to osimertinib. Longer follow-up is needed to establish if subsequent emergence of T790M could be a marker of resistance. https://ddd.uab.cat/record/238826 https://dx.doi.org/urn:doi:10.18632/oncotarget.25478 |
| spellingShingle | Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer Morán, Teresa EGFR-T790M mutation Serum/plasma Osimertinib Acquired resistance EGFR tyrosine kinase inhibitors |
| title | Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer |
| title_full | Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer |
| title_fullStr | Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer |
| title_full_unstemmed | Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer |
| title_short | Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer |
| title_sort | Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer |
| topic | EGFR-T790M mutation Serum/plasma Osimertinib Acquired resistance EGFR tyrosine kinase inhibitors |
| topic_facet | EGFR-T790M mutation Serum/plasma Osimertinib Acquired resistance EGFR tyrosine kinase inhibitors |
| url | https://ddd.uab.cat/record/238826 https://dx.doi.org/urn:doi:10.18632/oncotarget.25478 |